{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:17:04Z","timestamp":1793902624103,"version":"4.8.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA013696"],"award-info":[{"award-number":["P30CA013696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189960"],"award-info":[{"award-number":["UG1CA189960"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA013696"],"award-info":[{"award-number":["P30CA013696"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189960"],"award-info":[{"award-number":["UG1CA189960"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millenium"},{"DOI":"10.13039\/100016875","name":"Chimerix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018212","name":"Orbus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS penetration. The purpose of this study was to determine the maximum-tolerated dose of intrathecal trastuzumab and its efficacy in patients with HER2-positive leptomeningeal disease (LMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter study enrolled 34 LMD patients in a combined phase I\/II study in treating patients with intrathecal trastuzumab. Any HER2-positive histology was allowed in the phase I; the phase II was limited to HER2-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Intrathecal trastuzumab was well-tolerated, with one dose limiting toxicity of grade 4 (arachnoiditis) occurring at the 80 mg twice weekly dose. The recommended phase II dose was 80 mg intrathecally twice weekly. Twenty-six patients at dose level 80 mg were included in evaluation for efficacy: partial response was seen in 5 (19.2%) patients, stable disease was observed in 13 (50.0%), and 8 (30.8%) of the patients had progressive disease. Median overall survival (OS) for phase II dose treated patients was 8.3 months (95% CI 5.2\u201319.6). The phase II HER2-positive breast cancer patients median OS was 10.5 months (95% CI 5.2\u201320.9). Pharmacokinetic (PK) studies were limited in the setting of concurrent systemic trastuzumab administration, however, did show stable cerebrospinal fluid (CSF) concentrations with repeated dosing suggest that trastuzumab does not accumulate in the CSF in toxic concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests promise for potentially improved outcomes of HER-positive LMD patients when treated with intrathecal trastuzumab while remaining safe and well-tolerated for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noac195","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T19:41:24Z","timestamp":1660160484000},"page":"557-565","source":"Crossref","is-referenced-by-count":86,"title":["A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-0677","authenticated-orcid":false,"given":"Priya U","family":"Kumthekar","sequence":"first","affiliation":[{"name":"Department of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Avram","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Emeritus Northwestern University Feinberg School of Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B","family":"Lassman","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rush University Medical Center , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L","family":"Bell Burdett","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Division of Biostatistics, Feinberg School of Medicine, Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas V","family":"Lukas","sequence":"additional","affiliation":[{"name":"Department of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Dixit","sequence":"additional","affiliation":[{"name":"Department of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Perron","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery at The Feinberg School of Medicine at Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Division of Biostatistics, Feinberg School of Medicine, Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Gradishar","sequence":"additional","affiliation":[{"name":"Department of Medicine at The Feinberg School of Medicine at Northwestern University at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I","family":"Pentsova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Jeyapalan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tufts Medical Center , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris D","family":"Groves","sequence":"additional","affiliation":[{"name":"Texas Oncology-Austin Brain Tumor Center , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Melisko","sequence":"additional","affiliation":[{"name":"Department of Medicine at the University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J","family":"Raizer","sequence":"additional","affiliation":[{"name":"Department of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","article-title":"Leptomeningeal carcinomatosis in patients with breast cancer","volume":"135","author":"Franzoi","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1186\/s12885-015-2042-y","article-title":"Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients","volume":"15","author":"Mittica","year":"2015","journal-title":"BMC Cancer."},{"issue":"6","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M","article-title":"Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment","volume":"67","author":"Boogerd","year":"1991","journal-title":"Cancer."},{"issue":"5","key":"2023031415484728100_","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.breast.2014.06.009","article-title":"Metastatic breast cancer subtypes and central nervous system metastases","volume":"23","author":"Aversa","year":"2014","journal-title":"Breast."},{"issue":"22","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1073\/pnas.89.22.10578","article-title":"Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease","volume":"89","author":"Guy","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"issue":"20","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol."},{"issue":"3","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejca.2003.09.018","article-title":"Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment","volume":"40","author":"Shmueli","year":"2004","journal-title":"Eur J Cancer."},{"issue":"35","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.3748\/wjg.v22.i35.7926","article-title":"HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists","volume":"22","author":"Fusco","year":"2016","journal-title":"World J Gastroenterol."},{"issue":"5","key":"2023031415484728100_","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer."},{"issue":"2","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/02841860500486630","article-title":"Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab","volume":"45","author":"Yau","year":"2006","journal-title":"Acta Oncol."},{"issue":"11","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1526-8209(11)70419-0","article-title":"Use of intrathecal trastuzumab in a patient with carcinomatous meningitis","volume":"2","author":"Laufman","year":"2001","journal-title":"Clin Breast Cancer."},{"issue":"8","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","article-title":"Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report","volume":"19","author":"Stemmler","year":"2008","journal-title":"Anticancer Drugs."},{"issue":"5","key":"2023031415484728100_","first-page":"1373","article-title":"Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer","volume":"15","author":"Stemmler","year":"2006","journal-title":"Oncol Rep."},{"issue":"3","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J Neurooncol."},{"issue":"4","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jocn.2014.10.022","article-title":"Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities","volume":"22","author":"Kak","year":"2015","journal-title":"J Clin Neurosci."},{"issue":"3","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11060-020-03555-z","article-title":"Cerebrospinal fluid circulating tumor cells as a quantifiable measure of leptomeningeal metastases in patients with HER2 positive cancer","volume":"148","author":"Malani","year":"2020","journal-title":"J Neurooncol."},{"issue":"1","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs."},{"issue":"11","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol."},{"issue":"21","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel","volume":"21","author":"Leyland-Jones","year":"2003","journal-title":"J Clin Oncol."},{"issue":"2","key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-018-3728-z","article-title":"Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin((R))), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors","volume":"83","author":"Quartino","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"key":"2023031415484728100_","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac195\/46040473\/noac195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/3\/557\/49523457\/noac195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/3\/557\/49523457\/noac195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T08:55:25Z","timestamp":1700902525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/3\/557\/6660706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,10]]},"published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac195","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,8,10]]}}}